Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies
Open accessThe DOI matches its Crossref record; 153 of the 156 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Incomplete adherence to tuberculosis (TB) treatment increases the risk of delayed culture conversion with continued transmission in the community, as well as treatment failure, relapse, and development or amplification of drug resistance. We conducted a systematic review and meta-analysis of adherence interventions, including directly observed therapy (DOT), to determine which approaches lead to improved TB treatment outcomes. METHODS AND FINDINGS: We systematically reviewed Medline as well as the references of published review articles for relevant studies of adherence to multidrug treatment of both drug-susceptible and drug-resistant TB through February 3, 2018. We included randomized controlled trials (RCTs) as well as prospective and retrospective cohort studies (CSs) with an internal or external control group that evaluated any adherence intervention and conducted a meta-analysis of their impact on TB treatment outcomes. Our search identified 7,729 articles, of which 129 met the inclusion criteria for quantitative analysis. Seven adherence categories were identified, including DOT offered by different providers and at various locations, reminders and tracers, incentives and enablers, patient education, digital technologies (short message services [SMSs] via mobile phones and video-observed therapy [VOT]), staff education, and combinations of these interventions. When compared with DOT alone, self-administered therapy (SAT) was associated with lower rates of treatment success (CS: risk ratio [RR] 0.81, 95% CI 0.73-0.89; RCT: RR 0.94, 95% CI 0.89-0.98), adherence (CS: RR 0.83, 95% CI 0.75-0.93), and sputum smear conversion (RCT: RR 0.92, 95% CI 0.87-0.98) as well as higher rates of development of drug resistance (CS: RR 4.19, 95% CI 2.34-7.49). When compared to DOT provided by healthcare providers, DOT provided by family members was associated with a lower rate of adherence (CS: RR 0.86, 95% CI 0.79-0.94). DOT delivery in the community versus at the clinic was associated with a higher rate of treatment success (CS: RR 1.08, 95% CI 1.01-1.15) and sputum conversion at the end of two months (CS: RR 1.05, 95% CI 1.02-1.08) as well as lower rates of treatment failure (CS: RR 0.56, 95% CI 0.33-0.95) and loss to follow-up (CS: RR 0.63, 95% CI 0.40-0.98). Medication monitors improved adherence and treatment success and VOT was comparable with DOT. SMS reminders led to a higher treatment completion rate in one RCT and were associated with higher rates of cure and sputum conversion when used in combination with medication monitors. TB treatment outcomes improved when patient education, healthcare provider education, incentives and enablers, psychological interventions, reminders and tracers, or mobile digital technologies were employed. Our findings are limited by the heterogeneity of the included studies and lack of standardized research methodology on adherence interventions. CONCLUSION: TB treatment outcomes are improved with the use of adherence interventions, such as patient education and counseling, incentives and enablers, psychological interventions, reminders and tracers, and digital health technologies. Trained healthcare providers as well as community delivery provides patient-centered DOT options that both enhance adherence and improve treatment outcomes as compared to unsupervised, SAT alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



























Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The consequences of poor adherence include delayed sputum culture conversion, treatment failure, relapse, prolonged infectiousness, development of drug resistance, and increased morbidity and mortality [4,5].”
From Psychosocial Interventions for Improving Treatment Adherence in Tuberculosis Patients: A Scoping Review of Evidence-Based Approaches. (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous research has indicated that treatment adherence interventions (eg, patient counselling and education, reminders, and digital health technologies)47, 48 and social protection interventions (eg, cash transfers and economic incentives)49, 50 can increase treatment adherence and prevent mortality.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
(2014) · Medical Entomology and Zoology · Cited by 17,633
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Free, C., Phillips, G., Galli, L., Watson, L., Felix, L., Edwards, P., Patel, V., & Haines, A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001362 · Cited by 1,766 · cited 1×
“Psychological interventions aim to support via psychological or emotional counseling or a social network of peers undergoing TB treatment as a means of improving adherence to TB treatment [18,19].”
BackgroundNahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw376 · Cited by 1,170
Self-citationPatient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative Research
Munro, S. A., Lewin, S. A., Smith, H. J., Engel, M. E., Fretheim, A., & Volmink, J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040238 · Cited by 1,080
Assessing the Gold Standard — Lessons from the History of RCTs
Bothwell, L. E., Greene, J. A., Podolsky, S. H., & Jones, D. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmms1604593 · Cited by 664
Directly observed therapy for treating tuberculosis
Karumbi, J., & Garner, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003343.pub4 · Cited by 644
The Effect of Directly Observed Therapy on the Rates of Drug Resistance and Relapse in Tuberculosis
Weis, S. E., Slocum, P. C., Blais, F. X., King, B., Nunn, M., Matney, G. B., Gomez, E., & Foresman, B. H. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404283301702 · Cited by 589 · cited 2×
“Only three CSs compared the impact of DOT on the development of drug resistance compared with SAT, one of which found no significant difference [4,59,70].”
BackgroundResultOrenstein, E. W., Basu, S., Shah, N. S., Andrews, J. R., Friedland, G. H., Moll, A. P., Gandhi, N. R., & Galvani, A. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70041-6 · Cited by 540
Research works printed but not linked: 7
- Alipanah N, Jarlsberg L, Miller C, Lechner A, Wai K, Nahid P. Report for Systematic Review for Adherence Interventions in TB Treatment. World Health Organization guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017;Annex 5.
- Review Manager (RevMan). 5.3 ed Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration; 2014.
- Vieira AA, Ribeiro SA. Compliance with tuberculosis treatment after the implementation of the directly observed treatment, short-course strategy in the city of Carapicuiba, Brazil. J Bras Pneumol. 2011; 37(2): 223– 31. Epub 2011/05/04.. 21537659
- Arora VK S N.; Gupta R. Community mediated domiciliary DOTS execution—A study from New Delhi. Ind J Tub. 2003; 50: 143– 50.
- Cantalice Filho JP. Food baskets given to tuberculosis patients at a primary health care clinic in the city of Duque de Caxias, Brazil: effect on treatment outcomes. J Bras Pneumol. 2009; 35(10): 992– 7. Epub 2009/11/18.. 19918632
- Paramasivan RP, R. T.; Rajasekaran S. Short course chemotherapy: A controlled study of indirect default retrieval method. Ind J Tub. 1993; 40: 185– 90.
- A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre. Int J Tuberc Lung Dis. 1997; 1(6): 509– 17. Epub 1998/03/06.. 9487448
Cited by
Items 101–200 of 503
Ji, L., Mijiti, P., Chuangyue, H., Qian, G., Weiguo, T., & Jihong, C. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1134938 · Cited by 18
Prevalência e fatores associados ao abandono do tratamento da tuberculose
Sousa, G. J. B., Maranhão, T. A., Leitão, T. D. M. J. S., Souza, J., Moreira, T. M. M., & Pereira, M. L. D. (2021) · Revista da Escola de Enfermagem da USP · doi:10.1590/s1980-220x2020039203767 · Cited by 31
“One of them is directly observed therapy (DOT), which helps patients with regular medication intake, as well as alternatives to DOT, as observed through video(17-18).”
O'Donnell, M. R., Padayatchi, N., Wolf, A., Zelnick, J., Daftary, A., Orrell, C., Nimmo, C., Baldwin, M., Boodhram, R., Maharaj, B., et al. (2022) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002940 · Cited by 17
Kadota, J. L., Nabwire, S., Nalugwa, T., White, J. S., Cattamanchi, A., Katamba, A., & Shete, P. B. (2021) · Value in Health Regional Issues · doi:10.1016/j.vhri.2020.12.005 · Cited by 16
Interventions for High-Burden Infectious Diseases in Children and Adolescents: A Meta-analysis
Khan, D. S. A., Naseem, R., Salam, R. A., Lassi, Z. S., Das, J. K., & Bhutta, Z. A. (2022) · PEDIATRICS · doi:10.1542/peds.2021-053852c · Cited by 22
Wang, N., Guo, L., Shewade, H. D., Thekkur, P., Zhang, H., Yuan, Y., Wang, X., Wang, X.-L., Sun, M., Huang, F., et al. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00818-3 · Cited by 17
“Unfortunately, when compared with DOT alone, SAT was associated with lower rates of treatment success, adherence, and sputum smear conversion as well as higher rates of development of drug resistance [5, 6].”
Meca, A.-D., Mititelu-Tarțău, L., Bogdán, M., Dijmărescu, L. A., Pelin, A.-M., & Foia, L. G. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040569 · Cited by 22
“was completely discovered and introduced into the guidelines [72,90,94].”
BackgroundMarks, S. M., Self, J. L., Venkatappa, T. K., Wolff, M. B., Hopkins, P. B., Augustine, R. J., Khan, A., Schwartz, N. G., Schmit, K. M., & Morris, S. B. (2023) · Public Health Reports · doi:10.1177/00333549221148173 · Cited by 22
“9 46-48 In-person directly observed therapy might reduce the likelihood of robbery or assault of PEH compared with self-administered treatment because TB medications might be mistaken by others to have street value.”
BackgroundTodowede, O. O., Afaq, S., Adhikary, A., Kanan, S., Shree, V., Jennings, H. M., Faisal, M. R., Nisar, Z., Khan, I., Desai, G., et al. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09783-z · Cited by 19
Chen, J., Jiang, Y., Li, Z., Zhang, M., Liu, L., Li, A., & Lu, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-74942-z · Cited by 16
“In alignment with Article 21 of the Measures of the People’s Republic of China on the Management of Tuberculosis, TB patients are entitled to health insurance coverage for examinations and medication during treatment, with both national and local governments offering subsidies and exemptions for medical expenses relat…”
BackgroundRiquelme-Miralles, D., Palazón‐Bru, A., Sepehri, A., & Gil-Guillén, V. F. (2019) · Heart & Lung · doi:10.1016/j.hrtlng.2019.05.001 · Cited by 18
Ren, J., Han, D., Zhang, J., Wang, Y., Huang, Q., Tian, T., & Li, X. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s330225 · Cited by 16
Doltu, S., Ciobanu, A., Sereda, Y., Persian, R., Ravenscroft, L., Kasyan, L., Truzyan, N., Dadu, A., & Reid, A. J. S. (2021) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.14601 · Cited by 16
McKay, B., Castellanos, M. E., Ebell, M. H., Whalen, C. C., & Handel, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217219 · Cited by 17
“Our systematic review generated 166 unique results, 11 [39–49] studies compared DOT and SAT treatment outcomes in a prospective manner (Fig 1).”
ResultInfluentialKarat, A. S., Jones, A. S. K., Abubakar, I. I., Campbell, C., Clarke, A. L., Clarke, C. S., Darvell, M., Hill, A. T., Horne, R., Kunst, H., et al. (2021) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2021.100233 · Cited by 15
“Treating TB disease currently requires at least six months of daily therapy [2,3]; non-adherence to anti-TB therapy (ATT) worsens individual outcomes [4], increases the risk of drug-resistant TB (DR-TB) [5,6], and may prolong infectiousness [7].”
Hassani, S., Shahboulaghi, F. M., Foroughan, M., Nadji, S. A., Tabarsi, P., & Harouni, G. G. (2023) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2023/4056548 · Cited by 28
“…and delay in treatment completion, and as a result of prolonged treatment process, there will be increased treat-ment costs, psychological complications [2, 14], recurrence of the disease, increased risk of drug resistance, and increased death rates related to disease [8, 11, 14–17].”
Karnan, A., Jadhav, U. S., Ghewade, B., Ledwani, A., & Shivashankar, P. (2024) · Cureus · doi:10.7759/cureus.52706 · Cited by 15
“These may include financial or material rewards that motivate patients and interventions addressing barriers like cost, distance, and medication availability [30].”
BackgroundInfluentialMeta-Analysis of Studies on the Effects of Digital Therapeutics
Seo, Y.-C., Yong, S. Y., Choi, W. W., & Kim, S. H. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14020157 · Cited by 22
“To achieve this goal, a selection of academic papers was conducted by referencing the studies of Matthews [11], Wu et al. [12], Alipanah et al. [13], and Webb et al. [14].”
MethodScreening for latent tuberculosis in migrants—status quo and future challenges
Petersen, E., Al-Abri, S., Al‐Jardani, A., Memish, Z. A., Aklillu, E., Ntoumi, F., Mwaba, P., Wejse, C. M., Zumla, A. I., & Alyaquobi, F. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107002 · Cited by 20
“Among migrant subpopulations, there was a generally positive effect of social interventions such as education, adherence coaching, peer counseling, or cultural interventions, particularly if combined with the use of shorter regimens [103] .”
BackgroundThe impact of structured counselling on patient knowledge at a private TB program in Karachi
Sajjad, S. S., Sajid, N., Fatimi, A. S., Maqbool, N., Baig‐Ansari, N., & Amanullah, F. (2019) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.36.icon-suppl.1713 · Cited by 15
Iribarren, S., Wallingford, J. K., Schnall, R., & Demiris, G. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.yjbinx.2019.100066 · Cited by 18
“[10] If efforts go unchanged, it is estimated that by 2050, multidrug-resistant TB could kill as many as 2.5 million people per year and cost the global economy up to US$16.7 trillion.”
BackgroundInfluentialde Groot, L., Straetemans, M., Maraba, N., Jennings, L., Gler, M. T., Marcelo, D., Mekoro, M., Steenkamp, P., Gavioli, R., Spaulding, A. C., et al. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7050065 · Cited by 16
Health counseling support medication adherence to regular pulmonary tuberculosis patients
Efendi, S., Sjattar, E. L., & Syam, Y. (2022) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2022.101055 · Cited by 14
Wu, Z., Lü, L., Li, Y., Chen, J., Zhang, Z., Ning, C., Yuan, Z., Pan, Q., Shen, X., & Zhang, W. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.923319 · Cited by 24
Campbell, J. R., Brode, S. K., Barry, P. M., Bastos, M. L., Bonnet, M., Guglielmetti, L., Kempker, R. R., Klimuk, D., Laniado-Laborı́n, R., Milanov, V., et al. (2023) · Thorax · doi:10.1136/thorax-2023-220249 · Cited by 14
“40 Finally, the number of participants in this analysis initiating treatment from 2013 to 2016 and receiving new/repurposed drugs of bedaquiline and linezolid were relatively few.”
BackgroundRusen, I. D. (2020) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed5020086 · Cited by 14
“Treatment interruption is associated with poor outcomes and development of further drug resistance [7].”
BackgroundAyakaka, I., Armstrong-Hough, M. J., Hannaford, A., Ggita, J. M., Turimumahoro, P., Katamba, A., Katahoire, A., Cattamanchi, A., Shenoi, S., & Davis, J. L. (2022) · Global Public Health · doi:10.1080/17441692.2021.2000629 · Cited by 16
“Interventions to ensure routine attendance at TB clinic visits, and, for people living with HIV and AIDS, adherence to both TB treatment and ART have been shown to reduce treatment interruption (Alipanah et al., 2018; Munro et al., 2007) Treatment adherence support has the potential to increase uptake of other related…”
BackgroundPerwitasari, D. A., Setiawan, D., Nguyen, T. N., Pratiwi, A., Fauziah, L. R., Saebrinah, E., Safaria, T., Nurulita, N. A., & Wiraagni, I. A. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/4044530 · Cited by 13
“Some interventions to increase adherence to TB patients include education, counseling, psychological intervention, reminders, and tracers [9].”
Chen, Y., Jiang, Q., Mijiti, P., Takiff, H. E., & Gao, Q. (2023) · eLife · doi:10.7554/elife.84815 · Cited by 15
Kósa, N., Zolcsák, Á., Voszka, I., Csı́k, G., Horváti, K., Horváth, L. B., Bősze, S. E., & Herényi, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052457 · Cited by 13
“Patient adherence to therapy is far from optimal due to the lengthy treatment and unwanted side effects of medicines [3,6].”
BackgroundBythrow, G. V., Mohandas, P., Güney, T., Standke, L. C., Germain, G. A., Lu, X., Ji, C. Y., Levendosky, K., Chavadi, S. S., Tan, D. S., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b01153 · Cited by 15
Variation in tuberculosis treatment outcomes and treatment supervision practices in Uganda
Berger, C. A., Kityamuwesi, A., Crowder, R. R., Lamunu, M., Tinka, L. K., Ggita, J. M., Sanyu, A. N., Namale, C., Oyuku, D., Chen, K. J., et al. (2020) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2020.100184 · Cited by 13
“A meta-analysis examining seven categories of adherence interventions identified that TB treatment outcomes improved with the use of CB-DOTS and trained health workers, as well as the use of patient education, incentives and enablers, psychological interventions, reminders and tracers and digital technologies [9].”
MethodChizimu, J. Y., Solo, E. S., Bwalya, P., Kapalamula, T. F., Mwale, K. K., Squarre, D., Shawa, M., Lungu, P., Barnes, D. A., Yamba, K., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12071126 · Cited by 12
“This may be the result of poor-compliance to medications, or inadequate treatment given to the patients [7].”
BackgroundClinical pharmacy services for tuberculosis management: a systematic review
Iskandar, D., Suryanegara, F. D. A., van Boven, J. F. M., & Postma, M. J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1186905 · Cited by 12
“This was in agreement with studies stating that health education improves TB prognosis (Westerlund et al., 2015) and treatment completion (Alipanah et al., 2018), leading to a reduction in the treatment default rate (Müller et al., 2018).”
BackgroundMethodResultBuilding bridges: multidisciplinary teams in tuberculosis prevention and care
Ramos, J. P., Vieira, M., Pimentel, C., Argel, M., Barbosa, P., & Duarte, R. (2023) · Breathe · doi:10.1183/20734735.0092-2023 · Cited by 22
Jeyashree, K., Thangaraj, J. W. V., Shanmugasundaram, D., Priya, G. S. L., Pandey, S., Janagaraj, V., Shanmugasundaram, P., Sabarinathan, R., Chadwick, J., Arunachalam, S., et al. (2024) · Global Health Action · doi:10.1080/16549716.2024.2363300 · Cited by 12
Milligan, H., Iribarren, S., Chirico, C., Telles, H., & Schnall, R. (2021) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2021.104421 · Cited by 14
Izhar, M. D., Butar, M. B., Hidayati, F., & Ruwayda, R. (2021) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2021.100872 · Cited by 20
Bianco, D. M., Maio, F. D., Santarelli, G., Palucci, I., Salustri, A., Bianchetti, G., Maulucci, G., Citterio, F., Sanguinetti, M., Tamburrini, E., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12010171 · Cited by 12
“The emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drugresistant tuberculosis (XDR-TB) and the high rate of patient non-compliance to therapy [3] due to the duration made the identification of novel potential treatment strategies a priority.”
BackgroundPietersen, E., Anderson, K., Cox, H. S., Dheda, K. U. J., Bian, A., Shepherd, B. E., Sterling, T. R., Warren, R. M., & van der Heijden, Y. F. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281097 · Cited by 17
Maha, A., Majumdar, S. S., Main, S., Phillip, W., Witari, K., Schulz, J., & du Cros, P. (2019) · Public Health Action · doi:10.5588/pha.18.0070 · Cited by 12
Barriers to Buruli ulcer treatment completion in the Ashanti and Central Regions, Ghana
Collinson, S., Frimpong, V. N. B., Agbavor, B., Montgomery, B., Oppong, M. N., Frimpong, M., Amoako, Y. A., Marks, M., & Phillips, R. O. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008369 · Cited by 12
“The use of DOT for similarly demanding treatment schedules, such as TB management, has shown some positive results; a recent meta-analysis found that DOT was associated with increased rates of TB treatment success compared to unobserved therapy, although the results for treatment completion and relapse were inconclusi…”
ResultWang, X., Qian, F., Zhou, M., & Li, Y. (2023) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2023.0084 · Cited by 11
“29,30 In addition, it has a social impact on reducing patient movement, thereby saving travel cost, time, and carbon emission.”
Katana, G. G., Ngari, M. M., Maina, T. W., Sanga, D., & Abdullahi, O. A. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00807-4 · Cited by 19
More Tailored Approaches to Tuberculosis Treatment and Prevention
Bark, C. M., Boom, W. H., & Furin, J. J. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-100622-024848 · Cited by 10
Lee, H., Bea, S., Kim, J. H., Jeong, H. E., Jang, S. H., Son, H., & Shin, J. (2024) · Public Health · doi:10.1016/j.puhe.2024.01.021 · Cited by 10
Overbeck, V., Malatesta, S., Carney, T., MYERS, B. J., Parry, C. D. H., Horsburgh, C. R., Theron, D., White, L. F., Warren, R. M., Jacobson, K. R., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09994-7 · Cited by 17
“In 1994, the World Health Organization (WHO) adopted the directly observed therapy (DOT), short-course strategy as a way to improve TB treatment adherence [12, 13].”
BackgroundEreso, B. M., Sagbakken, M., Gradmann, C., & Yimer, S. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-78084-0 · Cited by 11
“Furthermore, research shows that the use of adherence interventions, including patient education and counselling, reminders and digital health technologies, significantly improve TB treatment outcomes 37 .”
Saha, S., Saxena, D. B., Raval, D. A., Halkarni, N., Doshi, R., Joshi, M., Sridharan, M., Sathwara, J., Yasobant, S., Shah, H., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1021427 · Cited by 10
“In turn, low adherence increases the risk of poor outcomes, including treatment failure, relapse, and the development or amplification of drug resistance (6).”
BackgroundBibliometric analysis and evidence of clinical efficacy and safety of digital pills
Litvinova, O., Klager, E., Yeung, A. W. K., Tzvetkov, N. T., Kimberger, O., Kletečka-Pulker, M., Willschke, H., & Atanasov, A. G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1023250 · Cited by 15
Rafiei, R., Williams, C., Jiang, J., Aungst, T. D., Durrer, M., Tran, D., & Howald, R. (2021) · JMIR mhealth and uhealth · doi:10.2196/25406 · Cited by 15
“Nonetheless, issues surrounding adherence, patient administration techniques, disease self-management, and data outcomes at scale still persist despite product design innovation, and these are the next areas to be explored [14-18].”
BackgroundRisk Factors of Pulmonary Tuberculosis and Countermeasures: A Literature Review
Wikurendra, E. A., Nurika, G., Tarigan, Y. G., & Kurnianto, A. A. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.7287 · Cited by 10
“In addition, the enhanced integration technologies in terms of interconnection are often very important to track treatment in such a form that it would be comprehensive [6].”
BackgroundToft, A. L., Dahl, V. N., Sifna, A., Ige, O. M., Schwoebel, V., Souleymane, M. B., Piubello, A., & Wejse, C. M. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.015 · Cited by 10
Aspectos clínicos e epidemiológicos da tuberculose no estado do Amapá
Cardoso, R. F., Braga, F. A. G., Marçal, P. H. E. C., de Abreu, S. T. Q., Carvalho, D. M. D., da Silva, J. P., & Mota, Á. D. C. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n3-333 · Cited by 9
Makabayi‐Mugabe, R., Musaazi, J., Zawedde‐Muyanja, S., Kizito, E., Fatta, K., Namwanje, H., Turyahabwe, S., & Nkolo, A. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-10120-7 · Cited by 15
“Improvements in treatment success documented by community-based models are probably due to the convenience, decrease in care costs associated with home-based care [26] and lower rates of side effects associated with regimen type.”
BackgroundIsmail, N. A., Moultrie, H., Mwansa-Kambafwile, J. R. M., Copas, A. J., Rangaka, M. X., Izu, A., Moyo, S., Skinner, D. G., Ismail, F., Goscé, L., et al. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00816-8 · Cited by 15
“8 The counselling with conditional cash transfers intervention is a useful alternative to medication monitors which seek to achieve similar outcomes but do not directly address underlying factors related to patient education and costs.”
Law, S. J., Seepamore, B., Oxlade, O., Sikhakhane, N., Dawood, H., Chetty, S., Padayatchi, N., Menzies, D., & Daftary, A. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06136-1 · Cited by 9
“Innovative strategies that engage patients early on to prevent pre-treatment losses to follow-up, as well as during TB care to resolve unaddressed barriers to adherence, without burdening under-resourced health systems, are urgently needed [8, 9].”
BackgroundQiu, B., Tao, B., Liu, Q., Li, Z., Song, H., Tian, D., Wu, J., Wu, Z., Zhan, M., Lu, W., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.685368 · Cited by 9
Bartholomay, P., Pinheiro, R. S., Johansen, F. D. C., Pelissari, D. M., & de Araújo, W. N. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06756-7 · Cited by 14
McCrossan, P., O’Donoghue, D., McElnay, J. C., & Shields, M. D. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.965629 · Cited by 9
Bröckelmann, N., Stadelmaier, J., Harms, L., Kubiak, C., Beyerbach, J., Wolkewitz, M., Meerpohl, J. J., & Schwingshackl, L. (2022) · BMC Medicine · doi:10.1186/s12916-022-02559-y · Cited by 11
Zhang, M., Wang, G., Najmi, H., Yaqoob, A., Li, T., Xia, Y., Ye, J., Hou, S., Xiao, Y., Zhou, L., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1033532 · Cited by 12
de Lima, L. V., Pavinati, G., Palmieri, I. G. S., Vieira, J. P., Blasque, J. C., Higarashi, I. H., Fernandes, C. A. M., & Magnabosco, G. T. (2023) · Revista gaúcha de enfermagem · doi:10.1590/1983-1447.2023.20230077.pt · Cited by 9
Islam, F., Ahmad, H., Nurbaya, N., Ahmad, M., Ansar, Ramadhan, K., Syukri, M., Arrazy, S., Perdana, A. A., Siregar, D., et al. (2024) · Journal of Public Health and Pharmacy · doi:10.56338/jphp.v4i1.5022 · Cited by 24
Sodhi, R., Vatsyayan, V., Panibatla, V., Sayyad, K., Williams, J., Pattery, T., & Pal, A. (2024) · PLOS Digital Health · doi:10.1371/journal.pdig.0000421 · Cited by 14
Jiang, W., Li, Z., Zhao, Q., Gao, M., Long, Q., Wang, W., Huang, F., Wang, N., & Tang, S.-L. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00832-5 · Cited by 9
“Other interventions focusing on the management of DRTB patients, such as directly observed therapy, patient-centered support, and the use of e-health technologies, could also improve treatment adherence of MDR-TB patients [22, 23].”
BackgroundAsare, P. P. A., Osei-Wusu, S., Baddoo, N. A., Bedeley, E., Otchere, I. D., Brites, D., Loiseau, C., Asante-Poku, A., Prah, D. A., Borrell, S., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.110 · Cited by 9
Rao, J. S., Diwan, V., Kumar, A. A., Varghese, S. S., Sharma, U., Purohit, M. R., Das, A., & Rodrigues, R. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17865.1 · Cited by 11
Sharma, J. R., Dludla, P. V., Dwivedi, G., & Johnson, R. (2023) · Global Heart · doi:10.5334/gh.1191 · Cited by 13
Huda, M. H., Rahman, M. F., Zalaya, Y., Mukminin, M. A., Purnamasari, T., Hendarwan, H., Su’udi, A., Hasugian, A. R., Yuniar, Y., Handayani, R. S., et al. (2024) · PLOS ONE · doi:10.1371/journal.pone.0312001 · Cited by 8
Qin, N., Chen, J., Chen, L., Hu, W., Yan, F., Xu, C., Zhang, H., Hou, Y., Tang, L., Shen, X., et al. (2025) · BMJ Global Health · doi:10.1136/bmjgh-2024-018022 · Cited by 11
Dessie, G., Negesse, A., Wagnew, F., Amare, D., Tiruneh, B. Z., Mulugeta, H., Mekonnen, B. A., Haile, D. H., Ayalew, T. A., & Habtewold, T. D. (2020) · Current Therapeutic Research · doi:10.1016/j.curtheres.2020.100603 · Cited by 8
Александровна, П. Н., Vasilyeva, I. A., Samoylova, А. G., & Tyulkova, T. E. (2022) · Tuberculosis and lung diseases · doi:10.21292/2075-1230-2022-100-2-53-60 · Cited by 8
“Подобный подход имеет ряд недостатков: это принудительная модель, представляющая пациента в качестве пассивного получателя терапии [18], развивает стигматизацию больного [28], затратна для медицинских служб, а в некоторых странах и для пациентов, трудно реализуема в условиях географической удаленности [6, 8, 24], пото…”
Feng, Z., Miao, Y., Peng, Y., Sun, F., Zhang, Y., Li, R., Ge, S., Chen, X., Song, L., Li, Y., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08264-2 · Cited by 8
“The development of new and safe therapeutic strategies with potent bactericidal activity is the main approach to short treatment duration, improve compliance and ensure the success rate, thus reducing the burden of both doctors and patients [4].”
BackgroundThreats and Interventions During the Treatment of Tuberculosis in an Inner-city District
Jové, N., Masdeu, E., Brugueras, S., Millet, J.-P., Ospina, J. E., Orcau, À., Rius, C., Caylà, J. A., & Sánchez, F. (2020) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2020.05.025 · Cited by 8
Mesić, A., Ishaq, S., Khan, W. H., Mureed, A., Mar, H. T., Khaing, E. E., Aza, E. B., Rose, L., Lynen, L., Seddiq, M. K., et al. (2022) · Tropical Medicine & International Health · doi:10.1111/tmi.13716 · Cited by 8
“DOT has been used as an intervention to improve patient adherence and its modalities may be adapted, depending on who is providing it and where [16,17].”
BackgroundKwon, S., Nam, J. H., Kim, H., Park, H., & Kwon, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918344 · Cited by 10
“Directly observed therapy and public-private mix programs have been suggested to maximize adherence and require social and financial support (Lei et al., 2015; Alipanah et al., 2018).”
BackgroundRisk factors for disruptions in tuberculosis care in Uganda during the COVID-19 pandemic
Jackson, P., Zawedde‐Muyanja, S., Sekitoleko, I., Bbuye, M., Helwig, M., Padalkar, R., Hammad, M. B., Hopkinson, D. A., & Siddharthan, T. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001573 · Cited by 8
“Individuals without disruptions in care have a higher quality of life, when measured with validated tools, and less risk of developing multi-drug resistant tuberculosis [10].”
BackgroundLi, W., Su, M., Zhang, W., Fan, X., Li, R., Gao, Y., & Wei, X. (2023) · Health Research Policy and Systems · doi:10.1186/s12961-023-01054-x · Cited by 10
“Meanwhile, the majority of previous systematic reviews have focused on and compared the impact of several TB adherence and outcomes interventions [37, 38].”
BackgroundZhang, R., Pu, J., Zhou, J., Wang, Q., Zhang, T., Liu, S., Wang, G., Chen, Y., Liu, J., Hu, D., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07208-6 · Cited by 9
“One of the main challenges in the treatment of TB is non-adherence to treatment due to the long treatment period, modest tolerability, and complexity of drug regimens [4, 5].”
BackgroundAn Inca trail to the Holy Grail: digital medication adherence support for TB care
van Boven, J. F. M., & Alffenaar, J.-W. C. (2021) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0613 · Cited by 9
Ochonye, B. B., Sanni, F. O., Emmanuel, G. O., Umoh, P., Kalaiwo, A., Abang, R., Amechi, P., Ahkigbe, M., Akinpelumi, S., & Motilewa, O. O. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003461 · Cited by 11
“In previous studies, disruptions in treatment adherence have been associated with increased TB risk [46, 47].”
Kim, S., Pelissari, D. M., Harada, L. O., Sanchez, M. N., Bartholomay, P., Johansen, F. D. C., Maciel, E. L. N., Cohen, T., Castro, M. C., & Menzies, N. A. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf206 · Cited by 7
“Relapse, loss to follow-up, and drug-resistant TB were each strongly associated with increased mortality within the TB cohort, reflecting the harmful effects of interrupted or unsuccessful TB treatment [21–23].”
Dlozi, P. N., Ahmed, R., Khoza, S., & Dube, A. (2025) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2025.2499515 · Cited by 8
Herawati, F., Megawati, Y., Aslichah, I. N., Andrajati, R., & Yulia, R. (2021) · Pharmacy · doi:10.3390/pharmacy9020086 · Cited by 15
Wekesa, C., Sekaggya‐Wiltshire, C., Zawedde‐Muyanja, S., Lume, I., Nabaggala, M. S., Parkes-Ratanshi, R. M., & Adakun, S. A. (2023) · Trials · doi:10.1186/s13063-023-07314-z · Cited by 8
“In as much as MEMS technology may not be absolutely accurate in estimating patient adherence since opening the device may not imply drug ingestion, it does provide a patient-centred solution, relieving the burden on patients to meet an obligation of frequent clinic visits and maintaining patient autonomy [17].”
BackgroundVarela, L., Ortiz, J., García, P. K., Luna, L., Fuertes-Bucheli, J. F., & Pacheco, R. (2023) · Biomédica · doi:10.7705/biomedica.6961 · Cited by 7
“Previamente se ha reportado como útil la educación y el asesoramiento del paciente, los incentivos y los facilitadores, las intervenciones psicológicas, los recordatorios y los rastreadores, y las tecnologías de salud digital (40).”
BackgroundStandards for clinical trials for treating TB
du Cros, P., Greig, J. E., Alffenaar, J.-W. C., Cross, G. B., Cousins, C., Berry, C., Khan, U. A., Phillips, P. P. J., Velásquez, G. E., Furin, J. J., et al. (2023) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.23.0341 · Cited by 13
“Strategies to reduce participant drop-out are similarly diverse and variably described. security and financial incentives for every completed trial visit, 60 and transportation to visits.”
BackgroundImazu, P., dos Santos, J. M. M. F., Beraldi‐Magalhães, F., Fernández-Llimós, F., Tonin, F. S., & Pontarolo, R. (2022) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgac004 · Cited by 7
Foster, N., Tadesse, A. W., McQuaid, C. F., Goscé, L., Abdurhman, T., Assefa, D., Bedru, A., Houben, R. M. G. J., van Kalmthout, K., Letta, T., et al. (2023) · Trials · doi:10.1186/s13063-023-07289-x · Cited by 10
Kurbaniyazova, G., Msibi, F., Bogati, H., Kal, M., Sofa, A., Djama, E. A., Mozi, P., Hossain, F., Blasco, P., & Sannino, L. (2023) · Public Health Action · doi:10.5588/pha.22.0062 · Cited by 7
Ketidakpatuhan minum obat pada pasien TB paru: Studi kualitatif
Pasaribu, G. F., Handini, M. C., Manurung, J., Manurung, K., Sembiring, R., & Siagian, M. T. (2023) · Jurnal Prima Medika Sains · doi:10.34012/jpms.v5i1.3788 · Cited by 7
Ikram, A., Ali, A. M., Abbasi, S. H., Ashraf, N., Wali, S., Salman, M., Khan, M. A., Syed, N., & Ansari, J. A. (2020) · Journal of Tuberculosis Research · doi:10.4236/jtr.2020.84017 · Cited by 11
“These findings are consistent with findings from other countries [34] [35].”
ResultJiang, W., Peng, Y., Wang, X., Elbers, C., Tang, S., Huang, F., Chen, B., & Cobelens, F. G. J. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047023 · Cited by 6
Barreto‐Duarte, B., Villalva-Serra, K., Miguez-Pinto, J. P., Araújo‐Pereira, M., Campos, V. M. S., Rosier, G. L., Nogueira, B. M. F., Queiroz, A. T. L., Rolla, V. C., Cordeiro‐Santos, M., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae416 · Cited by 6
“Importantly, treatment adherence interventions, including directly observed treatment (DOT) provided by trained health-care professionals, as well as patient education and social protection, have been shown to greatly improve treatment success rates [11, 12].”
BackgroundVeronese, V., Miller, C. R., Ogundahunsi, O. A. T., den Boon, S., Xia, Y., Falzon, D., & Merle, C. S. (2023) · PLOS Digital Health · doi:10.1371/journal.pdig.0000182 · Cited by 7
“Disclaimer VV, CM, SDB, DF and CSM are currently employed by the World Health Organization; the authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy or views of the WHO.”
BackgroundInfluentialSelf-citationPiloting “From the Inside Out” — a toolkit addressing tuberculosis-related self-stigma
Macdonald, S. H.-F., France, N. F., Hodgson, I. J., Ali, F., Dewi, C., Abdurrakhman, I., Runtu, Y. M., Juan, A., Sugiharto, J., Byrne, E., et al. (2024) · BMC Global and Public Health · doi:10.1186/s44263-024-00062-5 · Cited by 9
Integrated Public-Private Partnerships to Combat Tuberculosis for Improving Economic Development
Srinivasan, S., Vallipriya, R., & Singh, A. K. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-9153-2.ch015 · Cited by 6
Treatment of Tuberculosis in Brazil—Past, Present, and Future Challenges
Jarovsky, D. (2019) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-019-0182-3 · Cited by 6
Brand, É. M., Rossetto, M., Calvo, K. D. S., Winkler, G. B., da Silva, D. A. R., Hentges, B., Machado, F. V., Duarte, Ê. R. M., da Silva, L. C., Vasques, S. C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222786 · Cited by 6
Metadata
- Authors
- Alipanah, N., Jarlsberg, L., Miller, C., Linh, N. N., Falzon, D., Jaramillo, E., & Nahid, P.
- Affiliations
- University of California, San Francisco (US)
- World Health Organization (CH)
- Corresponding author
- Nahid, Payam
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-07-03
- Volume
- 15
- Issue
- 7
- Pages
- e1002595
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC6029765
- OpenAlex
- W2810683857
- Cited by
- 503
- References
- 156
- Citations by year
- 2026: 48 · 2025: 75 · 2024: 79 · 2023: 88 · 2022: 75 · 2021: 67 · 2020: 42 · 2019: 26 · 2018: 3
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (publishedVersion)
- eScholarship (California Digital Library) (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
- Keywords
- tuberculosis, medication adherence, directly observed therapy, drug-resistant tuberculosis, self-administered therapy, sputum smear conversion, treatment failure, drug resistance development, incentives, patient education, video-observed therapy, mobile phone reminders, treatment success, relapse, transmission risk, multidrug therapy, patient-provider relationship
- MeSH terms
- Adolescent, Adult, Antitubercular Agents, Attitude of Health Personnel, Child, Child, Preschool, Health Personnel, Humans, Infant, Infant, Newborn, Health Knowledge, Attitudes, Practice, Patient Education as Topic, Risk Factors, Self Care, Tuberculosis, Video Recording, Randomized Controlled Trials as Topic, Treatment Outcome, Telemedicine, Directly Observed Therapy, Cell Phone, Medication Adherence, Text Messaging, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.